Malvern, PA (WiredPRNews.com) DermAvance Pharmaceuticals, a privately held pharmaceutical company specializing in advanced technology applications for skin health and cosmetic dermatology, introduced its’ first prescription product, HYDRO-Q (Hydroquinone 4%) Gel®.
HYDRO-Q 4% Gel represents a technological innovation in the formulation of prescription strength hydroquinone to significantly increase patient satisfaction and compliance with hyperpigmentation treatment. Presently, hydroquinone 4% is considered to be the gold standard in the topical treatment of hyperpigmentation and the only prescription strength approved by the FDA for use as a skin lightener. However, the currently marketed 4% hydroquinone cream formulations may not be cosmetically elegant for sensitive skin, oily skin or darker skin tones. Additionally, hydroquinone cream formulations easily oxidize when opened, resulting in patient callbacks and product returns. HYDRO-Q 4% Gel is the only FDA approved prescription strength hydroquinone formulated in an non-irritating aqueous based gel that will not oxidize.
“The unique advantage of HYDRO-Q 4% Gel is its ability to penetrate through the stratum corneum without irritation”, said W. Philip Werschler, MD/FAAD, board certified dermatologist and Assistant Clinical Professor at the University of Washington School of Medicine. “HYDRO-Q’s elegant formulation is well-tolerated by all Fitzpatrick skin types (I-VI), especially my acne patient population” commented Dr. Manjula Jegasothy, founder of Miami Skin Institute, Associate Clinical Professor of Dermatology at the University of Miami/ Miller School of Medicine.
HYDRO-Q 4% Gel (30g tube) is available through physician dispensing.
For more information contact:
DermAvance Pharmaceuticals, Inc.
274 West Lancaster Ave Suite 200
Malvern, PA 19355